The New Vision: Private Equity and the Remaking of Local Eye Care

WEST HARTFORD, CT – June 30, 2026 – For decades, Solinsky EyeCare has been a household name in the greater Hartford region, a trusted independent practice built by Dr. Alan Solinsky from the ground up. Today, that local legacy enters a new chapter, not by closing its doors, but by joining a much larger force: ReFocus Eye Health, a rapidly expanding, private equity-backed network of ophthalmology practices.

The announcement marks a significant moment for both Connecticut's healthcare landscape and the broader industry. With this strategic affiliation, Solinsky EyeCare's 11 locations and 14 specialists are now part of a network boasting over 250 physicians across 114 locations in the Northeast. While the press release assures patients that their trusted doctors and care teams will remain, the deal itself is a powerful case study in the immense wave of consolidation transforming specialized medicine. It's a story of scale, strategy, and the increasingly blurred lines between patient care and corporate growth.

The Anatomy of a Modern Healthcare Deal

At the heart of this partnership is the Management Services Organization (MSO) model, a structure that has become the primary vehicle for private equity investment in healthcare. ReFocus Eye Health, backed by healthcare-focused private equity firm Zenyth Partners since 2018, doesn't buy practices to run them clinically. Instead, it acquires the business operations—handling everything from human resources and billing to IT infrastructure and marketing.

“Solinsky EyeCare has spent decades earning the trust of Connecticut patients, and that legacy of exceptional, compassionate care is exactly what drew us to their practice,” said Jeff Rinkov, CEO of ReFocus Eye Health, in the official announcement. His statement underscores the MSO pitch: physicians are freed from administrative burdens to do what they do best.

The appeal for investors is clear. Ophthalmology is a fragmented, high-demand field fueled by an aging population and a lucrative mix of insurance-reimbursed procedures and cash-pay services like LASIK and premium cataract lenses. By consolidating dozens of practices like Solinsky, an MSO can achieve economies of scale, negotiate better rates with suppliers and insurers, and implement standardized, efficient business practices. While specific terms of the deal were not disclosed, industry analysts note that thriving ophthalmology platforms can command valuations between 11 and 15 times their earnings, making them highly attractive assets.

For practice owners, the motivations are equally compelling. “Joining ReFocus allows us to do exactly that—with more resources, and with the peace of mind that our physicians can remain focused on what matters most: our patients,” explained Dr. Alan Solinsky. For many independent founders, partnering with an MSO offers a solution to mounting administrative pressures, access to capital for cutting-edge technology they couldn't afford alone, and a structured succession plan that ensures their practice—and their legacy—continues.

What the Partnership Means for Connecticut Patients

On the surface, patients at Solinsky EyeCare's 11 locations from Hartford to Glastonbury will notice little change. The familiar names will remain on the door, and the same ophthalmologists and optometrists will conduct the exams. The promise is one of enhancement, not disruption. With the backing of ReFocus, the practice now has access to a deeper well of capital for new diagnostic equipment, facility upgrades, and recruiting more sub-specialists to the region.

Continuity of insurance coverage, a major concern for patients during such transitions, also appears stable. A review of accepted insurance plans shows significant overlap between what Solinsky EyeCare already accepts and the broader network of plans covered by other ReFocus-affiliated practices, suggesting minimal immediate disruption for the majority of patients.

However, the consolidation trend is not without its critics. Healthcare advocates often raise concerns that the efficiencies sought by corporate owners can subtly shift the focus from patient outcomes to patient throughput. "The question is always about the long-term incentives," noted one healthcare industry analyst. "When the owner is a private equity firm with a five-to-seven-year investment horizon, does that change how decisions are made about everything from patient scheduling to the choice of medical supplies?"

The 'Physician-Led' Promise

ReFocus Eye Health is keenly aware of this skepticism and has built its brand around countering it. The company's messaging heavily emphasizes a "physician-led, patient-first network," positioning its private equity backing not as a controlling force, but as a supportive foundation. The model, as they describe it, preserves clinical autonomy, allowing doctors to continue making all medical decisions without corporate interference.

"Our belief is that physicians should be empowered to practice at the highest level—focused on their patients, not paperwork," Rinkov stated. This narrative is a powerful recruiting tool for doctors weary of red tape.

The debate centers on the definition of "autonomy." While MSOs typically cede control over day-to-day clinical diagnoses, their influence over the business side is absolute. This can indirectly shape clinical practice. Decisions about which new technologies to purchase, which surgical lenses to stock, or how many patients a doctor is expected to see per hour are business decisions with direct clinical implications. ReFocus actively markets itself as a collaborative partner, stating that operational programs are "co-developed with physician input" to avoid the pitfalls of a top-down corporate structure.

A Widening Footprint

The Solinsky affiliation is not an isolated event but the latest in a string of high-profile partnerships that illustrate ReFocus's aggressive growth strategy. In March, the company announced a massive affiliation with Omni Ophthalmic Management Consultants, bringing a huge network of practices across New Jersey, Pennsylvania, and New York into its fold. In the past year alone, it has also partnered with major practices in the Washington D.C. area and Virginia, methodically building a dominant presence in the Northeast and Mid-Atlantic.

This rapid roll-up strategy is characteristic of the private equity playbook: acquire a "platform" practice, and then use it as a base to bolt on smaller, regional practices to quickly build scale and market share.

For Connecticut, the arrival of a major player like ReFocus signals a new competitive dynamic for the remaining independent ophthalmologists. The affiliation between a well-respected local institution and a powerful national network is a microcosm of the transformation happening across American healthcare, where the future of medicine is being forged at the crossroads of local practice, technological innovation, and big business.